Actualités de la communauté

24.01.2017 Anergis Appoints Klaus Schollmeier As New Chairman Of The Board Of Directors

  • Senior Pharma and Biotech Executive joins Anergis´ Board of Directors as New Chairman

EPALINGES, Switzerland, January 24, 2017 – Anergis SA, a Swiss clinical-stage biopharmaceutical company developing proprietary products for ultra-fast allergy immunotherapy, today announced the appointment of Dr. Klaus Schollmeier as Chairman of its Board of Directors.

More information

retour